Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2300071991Phase 3Not yet recruiting
Phase 3, randomised, open-label trial of surufatinib in apudoma (NET) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: progression-free survival. Planned start Apr 2023; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2300071991.